2022
DOI: 10.1111/ajco.13728
|View full text |Cite
|
Sign up to set email alerts
|

Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer

Abstract: Background RAS mutation testing now routinely informs the optimal management of metastatic colorectal cancer (mCRC), specifically the finding of a RAS mutation defines patients who will not benefit from treatment with an epidermal growth factor receptor inhibitor. Over time more RAS genes have been tested and more sensitive techniques used. Aims To review routine care RAS testing and results over time. Methods A retrospective analysis of the molecular data collected prospectively in the multi‐site Treatment of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 21 publications
0
0
0
Order By: Relevance